Laetose

Laetose is a preclinical sugar + myo-inositol small-molecule composition being developed by Impact Biomedical for metabolic and inflammatory applications, particularly diabetes. The product is described as a patented low-glycemic sugar composition in which myo-inositol functions as a sugar chaperone, with the proposed mechanism of action being mitigation or inhibition of tumor necrosis factor-alpha responses to sugar exposure and consequent anti-inflammatory effects. Company materials describe Laetose as containing less sugar than conventional sugar while aiming to preserve taste and performance, and position it for use in diabetes, inflammatory diseases, and broader metabolic conditions.

Brand names

Laetose

Other names

Laetoselow glycemic sugar composition